Skip to main content

Vaxcyte, Inc.

corporate_fare Company Profile

Vaxcyte, Inc.

PCVX·NASDAQ·Life Sciences·CIK 0001649094

We are a clinical-stage vaccine innovation company focused on developing vaccines to protect against bacterial diseases. We use our XpressCF™ cell-free protein synthesis platform to produce complex vaccines. This system aims to create high-fidelity vaccines with enhanced immunological benefits, which differs from conventional cell-based methods. The global vaccine market is large, durable, and growing, driven by routine pediatric vaccinations and increased adult vaccination due to new vaccines, expanded age recommendations, and international adoption. We target areas with significant unmet medical needs, including vaccines that offer broader protection against current and historical strains, and novel vaccines for pathogens without approved treatments. Our selection criteria for target disease areas and vaccine candidates include significant unmet medical need, clear commercial opportunity, efficient market adoption, acceptable biological risk, and established or acceptable clinical pathways. We are using our scalable cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Our pipeline includes PCV (Pneumococcal Conjugate Vaccine) candidates, which we believe are among the broadest-spectrum PCV candidates in development, targeting the approximately $8 billion global pneumococcal vaccine market. Pneumococcal disease (PD) is an infection caused by *Streptococcus pneumoniae* bacteria.

Vaxcyte, Inc. (NASDAQ:PCVX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PCVX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PCVX spans 8-K, 424B5, FWP, 10-Q.

Recent high-impact activity:

  • Vaxcyte's Q3 Loss Beats Estimates; VAX-31 BLA Filing Slated for 1H 2028
  • Vaxcyte Posts $297M Q3 Loss, $3.4B Pro Forma Cash, OPUS-2/3 Data in 1H 2027
  • Vaxcyte Closes Upsized $1.1B Concurrent Offerings After Full Over-Allotment Exercise
  • Vaxcyte Finalizes $500M Equity Offering at $64/Share Alongside $500M Convertible Notes
  • Vaxcyte Prices $1.15B Concurrent Offerings: $64/Share Common Stock and 1.50% Convertible Notes

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$766.63M
Diluted EPS
-$5.63
Op. Cash Flow
-$655.58M
Free Cash Flow
-$669.29M
Operating Income
-$923.67M
Cash & Equivalents
$173.96M
Debt / Equity
0.00×
Shares Outstanding
131.06M sh
Source: 10-K · filed 2026-02-24 · accession 0001649094-26-000007

Short Interest & Short Volume

6.72 days to cover

FINRA reported short interest of 15,359,758 shares in PCVX as of the October 30, 2026 settlement, a 5.0% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 19, 2026, 84.0% of PCVX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)15,359,758 shares as of October 30, 2026
Change vs prior period▲ 5.0%
Days to cover6.72 at avg daily volume of 2,284,738
Daily short volume (FINRA facilities)84.0% of 466,306 shares on November 19, 2026
5-day average short volume71.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PCVX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-08.

1 recent capital raise

Equity Offering Priced at $64.00/Share · Net Proceeds of ~$473M from Equity

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$55.3 -5.24% today
52-week range · as of 2026-11-04 $39.87 – $90.75
Market cap
$8.82B
Volume
1.3M (0.7× avg)
3-mo avg 1.8M
Live data · 2026-11-20 20:57 UTC · Market open

show_chartPrice Chart

Loading chart...

feed PCVX - Latest Insights

PCVX
Nov 04, 2026, 5:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $65.68
Real-time Price: $55.30 info
Change: -$10.38 (-16%) info
Market Cap: $8.82B info
PCVX
Oct 09, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.12
Real-time Price: $55.30 info
Change: -$15.82 (-22%) info
Market Cap: $8.82B info
PCVX
Oct 08, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $64.94
Real-time Price: $55.30 info
Change: -$9.64 (-15%) info
Market Cap: $8.82B info
PCVX
Oct 07, 2026, 6:05 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $66.40
Real-time Price: $55.30 info
Change: -$11.10 (-17%) info
Market Cap: $8.82B info
PCVX
Oct 06, 2026, 10:50 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $66.70
Real-time Price: $55.30 info
Change: -$11.40 (-17%) info
Market Cap: $8.82B info
PCVX
Oct 05, 2026, 9:24 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $72.50
Real-time Price: $55.30 info
Change: -$17.20 (-24%) info
Market Cap: $8.82B info
PCVX
Oct 05, 2026, 9:24 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $72.50
Real-time Price: $55.30 info
Change: -$17.20 (-24%) info
Market Cap: $8.82B info
PCVX
Oct 05, 2026, 4:28 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.00
Real-time Price: $55.30 info
Change: -$15.70 (-22%) info
Market Cap: $8.82B info
PCVX
Oct 05, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $87.80
Real-time Price: $55.30 info
Change: -$32.50 (-37%) info
Market Cap: $8.82B info
PCVX
Oct 05, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $72.80
Real-time Price: $55.30 info
Change: -$17.50 (-24%) info
Market Cap: $8.82B info
PCVX
Sep 03, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $60.41
Real-time Price: $55.30 info
Change: -$5.11 (-8%) info
Market Cap: $8.82B info
PCVX
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $58.11
Real-time Price: $55.30 info
Change: -$2.81 (-5%) info
Market Cap: $8.82B info
PCVX
Aug 05, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $55.92
Real-time Price: $55.30 info
Change: -$0.620 (-1%) info
Market Cap: $8.82B info
PCVX
Jun 02, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $47.41
Real-time Price: $55.30 info
Change: +$7.89 (+17%) info
Market Cap: $8.82B info
PCVX
May 06, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $57.10
Real-time Price: $55.30 info
Change: -$1.80 (-3%) info
Market Cap: $8.82B info
PCVX
May 06, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.10
Real-time Price: $55.30 info
Change: -$1.80 (-3%) info
Market Cap: $8.82B info
PCVX
May 06, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $57.10
Real-time Price: $55.30 info
Change: -$1.80 (-3%) info
Market Cap: $8.82B info
PCVX
Mar 23, 2026, 8:36 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $55.99
Real-time Price: $55.30 info
Change: -$0.690 (-1%) info
Market Cap: $8.82B info
PCVX
Mar 18, 2026, 7:34 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $54.20
Real-time Price: $55.30 info
Change: +$1.10 (+2%) info
Market Cap: $8.82B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets